We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

172 hedge funds and large institutions have $2.77B invested in Intercept Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 53 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 53

3% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 30

1% less funds holding

Funds holding: 173172 (-1)

10% less capital invested

Capital invested by funds: $3.09B → $2.77B (-$311M)

28% less call options, than puts

Call options by funds: $75.4M | Put options by funds: $105M

Holders
172
Holders Change
-1
Holders Change %
-0.58%
% of All Funds
4.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
31
Increased
63
Reduced
53
Closed
30
Calls
$75.4M
Puts
$105M
Net Calls
-$30M
Net Calls Change
-$17.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$545M +$3.28M +19,404 +0.5%
Ameriprise
2
Ameriprise
Minnesota
$428M +$172M +1,016,175 +55%
Capital World Investors
3
Capital World Investors
California
$234M +$26.5M +156,600 +11%
CG
4
Carmignac Gestion
France
$197M +$64.3K +380 +0%
O
5
OrbiMed
New York
$167M
Vanguard Group
6
Vanguard Group
Pennsylvania
$163M +$6.45M +38,092 +4%
First Trust Advisors
7
First Trust Advisors
Illinois
$87.9M +$21.1M +124,493 +27%
BFA
8
BlackRock Fund Advisors
California
$65.1M -$8.84M -52,194 -11%
BIT
9
BlackRock Institutional Trust
California
$62M +$1.42M +8,379 +2%
State Street
10
State Street
Massachusetts
$61.1M +$15.4M +91,189 +29%
Bank of America
11
Bank of America
North Carolina
$60.1M +$14M +82,669 +26%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$50.4M -$296K -1,750 -0.5%
JP Morgan Chase
13
JP Morgan Chase
New York
$47.2M +$1.79M +10,569 +3%
Credit Agricole
14
Credit Agricole
France
$40.9M +$8.48M +50,080 +22%
BB
15
BB Biotech
Switzerland
$38.2M +$7.62M +45,000 +21%
SAM
16
Sectoral Asset Management
Quebec, Canada
$32.9M +$67.7K +400 +0.2%
Deutsche Bank
17
Deutsche Bank
Germany
$28.7M +$3.29M +19,411 +11%
HCM
18
Highfields Capital Management
Massachusetts
$28.4M +$16.3M +96,300 +103%
CWAM
19
Columbia Wanger Asset Management
Illinois
$27.9M -$3.88M -22,946 -11%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$26.7M -$6.56M -38,726 -18%
AGA
21
Altrinsic Global Advisors
Connecticut
$26.4M -$1.33M -7,871 -4%
CCI
22
Columbus Circle Investors
$26.2M -$15.4M -90,710 -34%
UBS AM
23
UBS AM
Illinois
$20.4M +$19.6K +116 +0.1%
BA
24
BlackRock Advisors
Delaware
$18.7M +$1.09M +6,461 +5%
Norges Bank
25
Norges Bank
Norway
$18.4M

ICPT Hedge Fund Activity: Q4 2015 in Review

172 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2015, worth a combined $2.77B — down 10% from $3.09B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ICPT positions and 30 closed out — a net gain of 1 holder — while 63 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $172M. The largest seller was Fred Alger Management, cutting an estimated $62.5M.

  • 172 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2015, down from 173 in Q3 2015.
  • Funds reported $2.77B of Intercept Pharmaceuticals, Inc. stock for Q4 2015, down 10% quarter-over-quarter.
  • 31 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2015 and 30 closed out, a net change of +1 holder.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2015 was Ameriprise, an estimated $172M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2015 was Fred Alger Management, an estimated $62.5M sold.

Based on aggregated 13F filings for Q4 2015.